Evidence map›Paper›PMID 41928587›Full record

ArticleThe CRISPR journal2026

Toward Next-Gen Cell Therapy for Pediatric Patients: Neonatal Hepatocytes Tolerate Electroporation-Mediated Gene Editing and Engraft in the Liver.

Justin R Gibson, Abishek Dhungana, Menam Pokhrel, Benjamin Bessah Arthur, Olumide Adebayo, Daniel Hossack, Renee N Cottle

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The CRISPR journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Justin R GibsonDepartment of Bioengineering, College of Engineering, Computing, and Applied Sciences, Clemson University, Clemson, South Carolina, USA.
Abishek DhunganaDepartment of Bioengineering, College of Engineering, Computing, and Applied Sciences, Clemson University, Clemson, South Carolina, USA.
Menam PokhrelDepartment of Bioengineering, College of Engineering, Computing, and Applied Sciences, Clemson University, Clemson, South Carolina, USA.
Benjamin Bessah ArthurDepartment of Bioengineering, College of Engineering, Computing, and Applied Sciences, Clemson University, Clemson, South Carolina, USA.
Olumide AdebayoDepartment of Bioengineering, College of Engineering, Computing, and Applied Sciences, Clemson University, Clemson, South Carolina, USA.
Daniel HossackDepartment of Bioengineering, College of Engineering, Computing, and Applied Sciences, Clemson University, Clemson, South Carolina, USA.
Renee N CottleDepartment of Bioengineering, College of Engineering, Computing, and Applied Sciences, Clemson University, Clemson, South Carolina, USA.ORCID 0000-0002-7971-2865

Funding

Nonviral Delivery of CRISPR-Cas9 into Hepatocytes Combined with APAP Selection for Treatment of Familial HypercholesterolemiaR01HL168093 · NHLBI · CLEMSON UNIVERSITY · PI Renee Nicole Cottle · 2024 to 2026
$1.9M
NHLBI NIH HHS R01 HL168093
6 · The paper itself

Abstract

Hepatocyte transplantation (HTx) offers a safer, less invasive alternative to orthotopic liver transplantation for inherited metabolic liver diseases, especially in high-risk pediatric patients. Combining HTx with

Indexed as

Cell- and Tissue-Based TherapyElectroporationGene EditingHepatocytesAnimalsAnimals, NewbornCRISPR-Cas SystemsDisease Models, AnimalHumansHydrolasesLiverMiceMice, KnockoutTyrosinemiasfumarylacetoacetaseHydrolases

Identifiers

PMID41928587
PMCPMC13557426

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.